Zapatero, Almudena
Castro, Pablo
Roch, María
Carnero, Pablo Rodríguez
Carroceda, Sara
Rosciupchin, Alexandra Elena Stoica
Hernández, Sergio Honorato
Cogorno, Leopoldo
Iturriaga, Alfonso Gómez
García, David Büchser
Funding for this research was provided by:
This study was supported by funding from from Instituto De Investigación En Oncología Radioterápica (IRAD), Spain, Sociedad Española de Oncología Radioterápica (SEOR) and Janssen (CONVOCATORIA BECAS IRAD-FEOR 2023 BECAS JANSSEN IRAD-FEOR PARA PROYECTOS DE INVESTIGACIÓN EN CÁNCER DE PRÓSTATA)
Article History
Received: 24 January 2024
Accepted: 5 April 2024
First Online: 3 May 2024
Declarations
:
: This research complies with the Helsinki declaration and has been approved by the Ethics committee of the Hospital Universitario de La Princesa, Health Research Institute, Madrid (2023.5222).Trial registration: Clinicaltrials.gov identifier: NCT05919524; Registered 17 July 2023. Signature of the informed consent will be obtained from all patients before inclusion in the study.
: Not applicable.
: The authors declare that they have no competing interests. The analysis and monitoring of the data will be perfomed by a external and independent CRO.